$ILNS Letter To Shareholders Inside!! NEW YORK, March 29,

New Post Public Reply Private Reply Replies (0) Message Board
KoiCash

$ILNS Letter To Shareholders Inside!!

NEW YORK, March 29, 2013 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. ( ILNS ), a biopharmaceutical company engaged in the discovery and development of treatments for the prevention and treatment of neurodegenerative diseases, issued the following Letter to Shareholders from Dr. Daniel Chain, Chairman and CEO.

Dear Shareholder,

I would like to take this opportunity to update you briefly regarding my recent trip to Europe, which included 27 meetings in 10 days! The vast majority of these meetings had to do with the strategic plan I outlined in my letter to you of February 13, 2013: namely, to move forward aggressively with our CONJUMAB-A and tau immunotherapy programs, which have attracted interest from the pharmaceutical industry and institutional investors, especially in Europe.

I first attended the 11 th Annual Conference on Alzheimer's disease and Parkinson's disease from March 6-10. The conference provided the opportunity to meet with colleagues from the industry, as well as speak with several opinion leaders who shared their insights with me. A foremost topic of discussion centered on the FDA's new guidelines published in February this year, titled Guidance for Industry Alzheimer's Disease: Developing Drugs for the Treatment of Early Stage Disease. Taken at face value, the new guidelines are encouraging and represent an important departure from the FDA's previous position, in that they are designed to facilitate and accelerate AD drug development. At the same time, several industry experts cautioned against reading too much into the guidelines, stressing that the FDA has yet to ratify its position and will need to consider each New Drug Application on a case-by-case basis.

The conference comprised several interesting scientific presentations concerning the underlying pathophysiology of AD, as well as the potential of various therapeutic approaches. Not surprisingly, there were a large number of presentations centered on tau protein, which has become regarded as a key neurotoxicity mediator leading to irreversible damage and death of nerve cells. I was encouraged by several examples of assays being developed to evaluate drug compounds targeting tau that could be helpful to Intellect.

My next stop was the Bio-Europe Spring Conference held March 11-13. It was important for several reasons. First, it allowed me to present the company to a well-attended forum of industry specialists who clearly were interested to learn about our pipeline and strong partnering potential. People were fascinated to hear about our CONJUMAB platform and its initial focus on retinal degeneration. Second, the conference allowed me to conduct many one-on-one meetings, most of which were pre-arranged. Some of these meetings were with large pharmaceutical companies to discuss potential partnering relationships. Other pre-arranged meetings were with specialist contract research organizations and regulatory specialists that can help enormously with creating a high-value drug compound dossier to facilitate partnering activities in the future. I was pleased to discover a number of newly developed sophisticated tools that could be applied to test and optimize Intellect's drug candidates. Finally, the conference created an environment that encouraged new introductions and helped expand Intellect's network and visibility.

Back in New York, we have been exceedingly busy following up on ongoing licensing conversations and adding further detail to the development programs so that we are in position to proceed aggressively pending securing adequate financial resources.

Thank you for your continued support of Intellect and its important mission to create a world without Alzheimer's disease and other debilitating neurodegenerative diseases.

Sincerely,

Daniel Chain, PhD

Chairman and Chief Executive Officer

Safe Harbor Statement Regarding Forward- - Looking Statements:

The statements in this release and oral statements made by representatives of Intellect Neurosciences relating to matters that are not historical facts (including, without limitation, those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Intellect's product candidates and the sufficiency of Intellect's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, or Intellect's ability to fund such efforts with or without partners. Intellect undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly, any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Intellect's filings with the Securities and Exchange Commission, including those discussed in Intellect's Quarterly Report on Form 10-Q (file no. 333-128226), filed on February 12, 2013 and the risk factors discussed under the caption "Risk Factors" in Intellect's Annual Report on Form 10-K (file no. 333-128226), filed on October 15, 2012.

http://finance.yahoo.com/news/intellect-neuro...00705.html

Scroll down for more posts ▼

Top 10 Most Recent News Articles

University of Phoenix Poll Gets a Useful Reality Check

Updated Category News Views 31

Good Numbers, With the Usual Fine Print Employer approval is the kind of evidence career-focused schools desperately need, and University of Phoenix just put up a pretty loud batch of it. Among managers who directly supervise its graduates, 94% said the university understands employer needs, while 92% said its programs align with workforce demands. Those are stout...

Continue Reading
PCS Rental Prep Is About Control Before Distance Hits

Updated Category News Views 82

A vacant house can turn into a long-distance headache with startling speed. For military homeowners preparing for a PCS move, the useful point in Rhonda Leahy's guidance is not glamorous: settle the boring operational stuff before the moving boxes, travel orders, and new-duty-station chaos swallow the calendar. Renting out a former home is not merely collecting enough...

Continue Reading
West Virginia SEO Timelines Demand Patience, Not Hype

Updated Category News Views 68

A fresh website with no search footprint is not a race car; it is a pickup stuck in mud, and Sean O'Kelly's view of local SEO in West Virginia puts that inconvenient fact right on the table. Most businesses can expect measurable improvement after three to six months of consistent work, according to the HelloNation article. That is not a glamorous answer, but it is the...

Continue Reading
1031 Specialists Takes Tax Deferral to Public TV

Updated Category News Views 100

A tax rule most people ignore is getting a television spotlight. 1031 Specialists says it will appear on All Access with Andy Garcia, an educational series distributed to Public Television stations nationwide, to explain the 1031 exchange and its role in real estate investing. That is a sensible bit of exposure for a niche business built around a topic investors tend to...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 5

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
S&P Global's UBS AI Conference Slot Deserves Attention

Updated Category News Views 44

Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...

Continue Reading
Surfcomber Uses Art Week to Deepen Its Guest Appeal

Updated Category News Views 70

Miami Art Week can turn every hotel lobby into a billboard, but Surfcomber is at least trying to make its walls do some actual work. Kimpton Surfcomber Hotel is spreading local artists, participatory events, food, cocktails and retail across the property rather than hanging a few paintings and calling it culture. For a South Beach hotel with 200 feet of oceanfront, that...

Continue Reading
Sivers Moves Q3 Release to Accommodate U.S. Investors

Updated Category News Views 74

Thanksgiving has a nasty habit of turning perfectly ordinary earnings dates into ghost towns, and Sivers Semiconductors has sensibly stepped around that pothole. The company will publish its third-quarter 2026 interim report on Monday, November 30, rather than Thursday, November 26. That is not a strategy reset, a warning, or some grand corporate mystery. It is a calendar...

Continue Reading
PPL's January Dividend Keeps Utility Appeal Intact

Updated Category News Views 103

A dividend notice is rarely thrilling, but it can still separate a steady utility from a story stock peddling fumes. PPL Corporation declared a quarterly common dividend of $0.2850 per share on Nov. 20, payable Jan. 4, 2027. Shareholders must be on the books by Dec. 10, 2026, to receive it. Plain vanilla stuff, yes. Still, plain vanilla is often precisely why utility...

Continue Reading
Africa Tech Festival Puts Trust Ahead of AI Hype Cycle

Updated Category News Views 75

Fifteen thousand people can fill a convention centre, but they cannot magically deliver a package, fund a small business, or repair harm from a bad automated decision. That rather useful dose of reality ran through the final day of Africa Tech Festival 2026 in Cape Town. The 29th edition drew more than 15,000 delegates across three days, and the strongest message was not...

Continue Reading

Top 5 Most Recently Viewed Articles

Long-Term Efficacy of FINTEPLA in Managing Lennox-Gastaut Syndrome

Updated Category News Views 124

Long-Term Efficacy of FINTEPLA in Managing Lennox-Gastaut Syndrome FINTEPLA, known scientifically as fenfluramine, has demonstrated remarkable potential in treating seizures associated with Lennox-Gastaut syndrome (LGS) as confirmed by a significant open-label extension (OLE) study. This study emphasized the drug's beneficial effects, particularly in lowering seizure...

Continue Reading
Implications of U.S. Withdrawal from the Paris Agreement

Updated Category News Views 370

Significance of the U.S. Withdrawal from the Paris Agreement The decision by the U.S. to withdraw from the Paris Agreement is a critical moment not just for America, but for the entire globe. Analysts and climate diplomats suggest that this move will have far-reaching consequences, more profound than those witnessed during the initial exit in recent years. Accelerating...

Continue Reading
Ambarella's Oculii AI Technology Enhances Lotus Electric Vehicles

Updated Category News Views 236

Ambarella's Oculii AI Radar Transforms Lotus Vehicles In a major technological breakthrough, Ambarella has announced the worldwide rollout of its Oculii™ AI 4D imaging radar technology in Lotus's 2023 and 2024 electric vehicles. This advanced technology is integrated into the eye-catching Lotus Eletre electric hyper-SUV and the thrilling Lotus Emeya hyper-GT models....

Continue Reading
Luxury Brands Adapt to Broader Market with Affordable Options

Updated Category News Views 355

Luxury Brands Embrace Affordability for Wider Appeal In recent times, luxury brands have found themselves in a challenging position. With diminishing demand for high-priced items like $3,000 handbags and $4,000 cashmere jackets, many luxury labels are shifting their focus. They are creating a wider array of products targeting the middle-class customer, including...

Continue Reading
Elife Group's Game-Changing Platform for Global Transport Solutions

Updated Category News Views 328

Elife Group Launches Revolutionary Multi-Modal Travel Platform Elife Group has introduced an innovative multi-modal platform that redefines ground transportation. By seamlessly integrating rail and ride-hailing services into a single platform, they have created a comprehensive solution for travelers seeking convenient and efficient options. This strategic move positions...

Continue Reading